CKD-508 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses CKD-508 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- CKD-508 Tablet
- 3
Studies by the year they started
3 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses CKD-508 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy ParticipantsCompletedPhase 1Chong Kun Dang PharmaceuticalNCT06727396Written as CKD-508 Tablet
- A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male ParticipantsCompletedPhase 1Chong Kun Dang PharmaceuticalNCT06979973Written as CKD-508 Tablet
- Evaluation of the Safety and Tolerability of CKD-508 in Healthy SubjectsCompletedPhase 1Chong Kun Dang PharmaceuticalNCT04488900Written as CKD-508 Capsule